On April 8, 2021, Usynova Pharmaceuticals Ltd. and Wuxi Apptec Co., Ltd., a subsidiary of WuXi AppTec, signed a cooperation agreement on Class 1 innovative drugs in Shanghai. The signing ceremony was attended by Li Jinsong, Chairman of Usynova,Hu Tao, Chief Executive Officer, Peng Shengbin, Chief Scientific Officer, and Wang Xi, Vice President of Operations, Chen Shuhui, Research President of WuXi AppTec, Chen Zhizhong, Vice President of Domestic New Drug R&D Service Department, and related personnel.

Both parties reached a consensus on two Class 1 new drug collaborations for cancer and autoimmune diseases, dedicated to addressing unmet clinical needs, and WuXi AppTec will provide R&D services for Usynova in the area of small molecule innovative drugs. Leaders from both parties signed the cooperation agreement on behalf of the respective company. This milestone signing marks the all-round collaboration between the two parties in the field of small molecule innovative drug development, promoting more innovative drugs to the market for the benefit of patients worldwide and contributing to the pharmaceutical and health industry.

Dr. Hu Tao, CEO of Usynova, said in his speech:

Usynova is an innovative drug company dedicated to First-in-class/Best-in-class drug development. Its previous pipeline focused on recombinant proteins and monoclonal antibodies and is now actively expanding into small molecule targeted drugs. This time, we reached a cooperation intention and signed a contract with WuXi AppTec in a very short time, which reflects the cooperation sincerity and efficient execution of both parties. Going forward, Usynova will also carry out all-round and in-depth cooperation with many departments of WuXi AppTec.

Dr. Peng Shengbin, Chief Scientific Officer of Usynova, said:

Usynova focuses on the treatment of cancer and autoimmune diseases. Usynova conducts independent research and development on small molecule drug platforms aiming at novel and difficult targets, and accelerates the development process with the efficiency of partners. The two Class 1 new drugs in collaboration with WuXi AppTec are both global novel targets that are difficult to develop but have huge market potential. Usynova will accelerate the development of both projects and bring drugs to the global market as soon as possible by combining its extensive experience in targeted drug development and WuXi AppTec’s R&D capabilities in the field of small molecule innovative drugs.

Dr. Chen Shuhui, Research President of WuXi AppTec said:

WuXi AppTec has always been committed to helping its global partners accelerate the process of new drug development through an integrated new drug development platform, so that more new and good drugs can be put on the market as soon as possible to benefit patients worldwide.